Clinical trials: Fibrotic Lung Disease
Emphysema, Alveolitis, Fibrosing
Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
At present, a specific community based rehabilitation programme for lung or heart-lung transplant recipients does not exist. 160 hospitals throughout the United Kingdom (UK) offer pulmonary rehabilitation programmes.
- Conditions
- Emphysema, Alveolitis, Fibrosing, Cystic Fibrosis, Bronchiectasis
- Trial name
- NCT00129350
- Testing
- Pulmonary rehabilitation programme
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Idiopathic Pulmonary Fibrosis, Cough
Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)
Orally administered ME-015 (Suplatast Tosilate) has been available on the market as a prescription drug for allergy-related conditions in Japan since 1995 with a good safety and tolerability profile.
- Conditions
- Idiopathic Pulmonary Fibrosis, Cough, IPF, Fibrotic Lung Disease
- Trial name
- COSMIC-IPF (NCT05983471)
- Testing
- ME-015 (Suplatast Tosilate)
- Where
- 6 sites in India
- Volunteers
- 40 people
- Sponsor
- Melius Pharma AB
Idiopathic Pulmonary Fibrosis
Home Monitoring in Idiopathic Pulmonary Fibrosis; Improving Use of Anti-fibrotic Medication and Quality of Life
In this study it will be investigate whether a home monitoring program improves disease-specific health-related quality of life (HRQOL) for patients with idiopathic pulmonary fibrosis (IPF) through appropriate medication use and…
- Trial name
- NCT03420235
- Testing
- Home monitoring program
- Where
- Netherlands
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Usual Interstitial Pneumonia, Nonspecific Interstitial Pneumonia
Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial Pneumonias
The diagnosis of idiopathic interstitial pneumonia (IIP) is based on computed tomography (CT) imaging, whereas lung function studies are used for staging and follow up.
- Trial name
- Dm&Vc (NCT02596841)
- Volunteers
- 60 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans (BO)
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
This study investigates the safety and tolerability of Nintedanib in patients with bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell transplantation.
- Trial name
- NINBOST2018 (NCT03805477)
- Testing
- Nintedanib
- Where
- 3 sites in Saudi Arabia, Switzerland
- Volunteers
- 20 people
- Sponsor
- University Hospital, Basel, Switzerland
Fibrosis Lung, Respiratory Therapy
Automated Oxygen Titration During Walking in Patients With Lung Fibrosis (OXYWILD)
Fibrotic lung disease is a group of severe scarring lung diseases with a dismal prognosis, often leading to respiratory failure and need for oxygen treatment.
- Trial name
- OXYWILD (NCT06465654)
- Testing
- Automated variable dose oxygen treatment, Fixed dose oxygen treatment
- Where
- Denmark
- Volunteers
- 29 people
- Sponsor
- Janne Hastrup Jensen
Interstitial Lung Disease, Fibrotic Lung Disease
Self-efficacy and Well-being of Patients With Fibrotic Interstitial Lung Disease
Patients with fibrotic insterstitial lung disease (ILD) participating in inpatient rehabilitation or in outpatient pulmonary care will be invited to participate in this observational study.
- Conditions
- Interstitial Lung Disease, Fibrotic Lung Disease, Self Efficacy, Self-management
- Trial name
- NCT06027333
- Testing
- Inpatient rehabilitation (BRZ) or regular outpatient consultations (Insel), Blended patient education and self-management programme (PESM)
- Where
- 2 sites in Switzerland
- Volunteers
- 80 people
- Sponsor
- Berner Reha Zentrum AG
Idiopathic Pulmonary Fibrosis
Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes
Two oral medications, nintedanib and pirfenidone, were approved simultaneously by the FDA in October 2014 for the treatment of this disease.
- Trial name
- IPF-LTOS (NCT04316780)
- Testing
- Retrospective observational study- no intervention to occur.
- Where
- 8 sites in United States
- Volunteers
- 320 people
- Sponsor
- Steward St. Elizabeth's Medical Center of Boston, Inc.
Pulmonary Fibrosis
LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION
Prospective, observational, multicenter study that will evaluate the changes in lung function that patients admitted with SARS-CoV-2 pneumonia will present according to the level of severity at 4, 12, 26 and 52 weeks after…
- Trial name
- INC-CVD-202001 (NCT04409275)
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Pulmonary Hypertension, Interstitial Lung Disease
Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study
Over time, patients with fibrosing or interstitial lung disease (ILD) can develop high lung blood pressures (pulmonary hypertension), and this is associated with poorer prognosis and survival.
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia
- Trial name
- B-PHIT (NCT00637065)
- Testing
- Bosentan
- Where
- 3 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Idiopathic Pulmonary Fibrosis, Interstitial Pneumonia
Case-Control Study of Fibrotic Interstitial Lung Disease (ILD) and Cardiac Disease / Interventions.
There is a rare condition causing scarring of the lungs termed interstitial lung disease. This comprises a group of conditions which can be divided into separate diseases.
- Trial name
- NCT01154998
- Where
- United Kingdom
- Volunteers
- 360 people
- Sponsor
- St George's Healthcare NHS Trust
Pulmonary Fibrosis, Pulmonary Hypertension
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension
A randomized, double-blind, placebo-controlled dose escalation and verification study to assess the safety and efficacy of pulsed inhaled nitric oxide (iNO) in subjects at risk for pulmonary hypertension associated with pulmonary…
- Trial name
- REBUILD (NCT03267108)
- Testing
- INOpulse®, Open Label Extension
- Where
- 64 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- Bellerophon Pulse Technologies
Chronic Obstructive Pulmonary Disease, Bronchiectasis
Reducing Chronic Breathlessness in Adults by Following a Self-guided, Internet Based Supportive Intervention (SELF-BREATHE)
Background: Some health conditions make breathing difficult and uncomfortable. When this happens every day, it is called chronic breathlessness.
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchiectasis, Interstitial Lung Disease, Lung Cancer
- Trial name
- SELF-BREATHE (NCT06326957)
- Testing
- SELF-BREATHE
- Where
- United Kingdom
- Volunteers
- 246 people
- Sponsor
- King's College Hospital NHS Trust
Idiopathic Pulmonary Fibrosis, Obstructive Sleep Apnea
FIBRotic Interstitial Lung Disease and Nocturnal OXygen
Home sleep studies - which allow the measurement of breathing while the person sleeps - will be performed on patients with fibrotic interstitial lung disease attending two of the UK's largest respiratory medicine services.The…
- Conditions
- Idiopathic Pulmonary Fibrosis, Obstructive Sleep Apnea, Sleep Disturbance, Sleep Hypoventilation
- Trial name
- FIBRINOX (NCT04586946)
- Where
- 2 sites in United Kingdom
- Volunteers
- 102 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Scleroderma, Systemic, Interstitial Lung Disease
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD).
- Trial name
- SLSIII (NCT03221257)
- Testing
- Pirfenidone (PFD), Mycophenolate Mofetil (MMF)
- Where
- 16 sites in United States
- Volunteers
- 51 people
- Sponsor
- Michael Roth
Fibrotic Interstitial Lung Disease
Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease
Early antifibrotic therapy for f-ILD
- Trial name
- NCT07141810
- Testing
- Antifibrotic drugs (nidanib or pirfenidone)
- Volunteers
- 104 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Interstitial Lung Disease
Effects of Drinking Beetroot Juice on Exercise Performance in Patients With Fibrotic Interstitial Lung Disease
Exercise training as part of a structured pulmonary rehabilitation program is a key factor in improving quality of life and symptoms in people with interstitial lung disease (ILD).
- Trial name
- NCT04299945
- Testing
- concentrated beetroot juice (400mg of nitrate per serving), concentrated beetroot juice (trace amounts of nitrate per serving)
- Where
- 2 sites in Canada
- Volunteers
- 15 people
- Sponsor
- University of British Columbia
Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease
Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis
Purpose: To demonstrate the safety and efficacy of autologous Lung Spheroid Stem Cells (LSCs) administered by intravenous infusion in patients with idiopathic pulmonary fibrosis Progressive Fibrotic Interstitial Lung Disease.
- Trial name
- HALT-IPF (NCT04262167)
- Testing
- Lung Spheroid Stem Cells 100 million, Lung Spheroid Stem Cells 200 million
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
Lung Fibrosis Interstitial
Evaluation of the Pulmonary Fibrosis Learning and Self-management Programme (FILIP)
The goal of this observational study is to evaluate the feasibility and acceptability of a newly developed digital education and self-management program for people with fibrotic interstitial lung diseases (FILD) during inpatient…
- Trial name
- FILIP (NCT07457463)
- Testing
- Blended patient education and self-management programme
- Where
- 2 sites in Switzerland
- Volunteers
- 80 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Toward Self-management in ILD
Treating and caring for people with long term conditions accounts for a substantial proportion of health care resources. Self-management is advocated as a mechanism that can empower service users with long term conditions to…
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Connective Tissue Related ILD, Chronic Hypersensitivity Pneumonitis
- Trial name
- NCT03300583
- Testing
- Focus groups, Semi-structured interviews
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Kingston University